Mode
Text Size
Log in / Sign up
Phase 2 N=101 Randomized Double-blind Treatment

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

Enrolled (actual)
101
Serious AEs
2.0%
Results posted
Apr 2024
Primary outcome: Primary: Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 6; 4; 7; 7 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Pegozafermin (Drug); Placebo (Other)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
89bio, Inc.
Primary completion
Aug 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs)
6; 4; 7; 7; 8; 8
PRIMARY
Part 2: Number of Participants With TEAEs
18
PRIMARY
Part 1: Maximum Observed Serum Concentration (Cmax) of Pegozafermin
103; 439; 901; 1166; 649; 1674
PRIMARY
Part 1: Area Under the Serum Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Pegozafermin
11879; 42576; 95765; 112632; 78761; 209436
PRIMARY
Part 1: Time to Peak Serum Concentration (Tmax) of Pegozafermin
59.5; 48.0; 48.0; 48.1; 72.0; 48.0
PRIMARY
Part 1: Terminal Elimination Half-life (t1/2) of Pegozafermin
57.1; 46.3; 68.1; 53.0; 54.4; 53.2
PRIMARY
Part 2: Number of Participants With at Least a 2-point Improvement in NAFLD Activity Score (NAS) With at Least a 1-point Improvement in Ballooning or Lobular Inflammation, and no Worsening of Fibrosis
12
SECONDARY
Part 1: Number of Participants With a Positive Anti-Drug Antibodies (ADA) Response to Pegozafermin
1; 9; 7; 7; 11; 6
SECONDARY
Parts 1 and 2: Percent Change From Baseline in Body Weight
1.19; 2.59; 2.47; -0.80; 2.11; 2.64
SECONDARY
Parts 1 and 2: Percent Change From Baseline in Triglycerides, High Density Lipoprotein (HDL) Cholesterol (c), Non-HDLc, LDLc, Hemoglobin (HbA1C), Alanine Transaminase, Aspartate Aminotransferase, N-terminal Propeptide of Type III Collagen (Pro-C3)
-22.74; -23.95; -17.71; -27.63; -28.49; -20.71
SECONDARY
Part 1: Percent Change From Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) at Day 92
10.37; 7.40; 37.07; -41.42; -4.57; -41.11
SECONDARY
Part 1: Percent Change From Baseline in Adiponectin at Day 92
37.65; 25.46; 29.09; 60.85; 23.11; 24.14
SECONDARY
Part 1: Percent Change From Baseline in Free Fatty Acid at Day 92
28.70; 50.20; 27.08; 51.58; 43.85; 56.12
SECONDARY
Part 1: Percent Change From Baseline in Adipose Tissue Insulin Resistance (Adipo-IR) at Day 50
-6.12; 82.00; 3.28; 78.40; -25.96; -10.36
SECONDARY
Parts 1 and 2: Percent Change From Baseline in Liver Fat as Assessed Via Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)
-36.94; -49.62; -36.11; -60.39; -43.19; -50.39
SECONDARY
Part 2: Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of NASH
5
SECONDARY
Part 2: Number of Participants With NASH Resolution Without Worsening of Fibrosis
6

Summary

Part 1: This is a multi-center evaluation of pegozafermin (administered weekly or every other week) in a randomized, double-blind, placebo-controlled study administered for 12 weeks in participants with NASH and NAFLD at high risk of NASH, including a pre-defined number of participants with biopsy confirmed NASH and fibrosis stages F1-F3 to be enrolled. Part 2: This is a multi-center, open label evaluation of pegozafermin at 27 mg administered weekly for 20 weeks in participants with biopsy-proven NASH (NAS ≥4, fibrosis stage F2 or F3).

Eligibility Criteria

Key Inclusion Criteria

  • Participants must be 21 to 75 years of age inclusive, at the time of signing the informed consent form (ICF).
  • Evidence of steatosis by Fibroscan and magnetic resonance imaging based proton density fat fraction (MRI-PDFF)
  • NASH or NAFLD at high risk for NASH as reflected by AT LEAST ONE of the following:
  • Diagnosis of NASH with fibrosis (stages F1, F2 or F3), without cirrhosis, by percutaneous liver biopsy within 24 months prior to screening
  • Central obesity WITH type 2 diabetes mellitus (T2DM)
  • Central obesity WITH either increased alanine transaminase (ALT) and/or Fibroscan vibration-controlled transient elastography (VCTE) score ≥7 KPa.
  • Part 2 only: Biopsy-proven NASH in a liver biopsy obtained within 24 weeks of baseline with fibrosis stage F2 or F3 and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation. A small number of high risk F1 allowed.

Key Exclusion Criteria

  • Clinically significant disorder or a history of any illness that, in the opinion of the Investigator, might confound the results of the study, or pose additional risk to the participant by participation in the study.
  • History of type 1 diabetes.
  • Weight loss of more than 5% within 3 months prior to Day -1 or more than 10% within 6 months prior to Day -1 or planning to try to lose weight during conduct of study.
  • History of a liver disorder other than NASH or clinical suspicion of a liver disorder other than NASH
  • History of cirrhosis or evidence of cirrhosis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04048135). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search